{"version": "https://jsonfeed.org/version/1.1", "title": "Sharemaestro Newsreel: Germany Biotechnology news", "home_page_url": "https://sharemaestro.com/newsreel/de/healthcare/biotechnology/", "feed_url": "https://sharemaestro.com/newsreel/de/healthcare/biotechnology/feed.json", "description": "Latest Biotechnology company headlines from Germany, newest first, with source links and direct routes to company research and sentiment.", "language": "en", "items": [{"id": "source:0900c281a1b7e54999dfd196bbfe90a2a2a5cb52fdbe999e1d2a91793c625390", "url": "https://finance.yahoo.com/healthcare/articles/pfizer-valneva-lyme-disease-vaccine-050000585.html", "external_url": "https://finance.yahoo.com/healthcare/articles/pfizer-valneva-lyme-disease-vaccine-050000585.html", "title": "Pfizer and Valneva\u2019s Lyme Disease Vaccine Candidate Marketing Authorization Application Validated by European Medicines Agency", "content_text": "Submission based on favorable efficacy and safety results from Phase 3 VALOR trial NEW YORK & LYON, France, August 14, 2026--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announced that the European Medicines Agency (EMA) has validated the Marketing Authorization Application (MAA) for PF-07307405, the companies' 6-valent outer surface protein A (OspA)-based Lyme disease vaccine candidate and will begin its assessment of the application. The application is based on encouraging efficacy of more than 70% observed in the Phase 3 VALOR \"Vaccine Ag", "date_published": "2026-08-14T05:00:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "AYJ"], "_sharemaestro": {"country": "Germany", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "AYJ", "name": "Valneva SE", "sentiment_url": "https://sharemaestro.com/sentiment/72be05a1-645b-4461-92f2-b776ddee3ee3/"}]}}, {"id": "source:248772e86f849c54af48203e1ed82ca5c5a36ecd4687869763f578f9e29f78bd", "url": "https://finance.yahoo.com/healthcare/articles/could-abbvie-inc-abbv-win-233835472.html", "external_url": "https://finance.yahoo.com/healthcare/articles/could-abbvie-inc-abbv-win-233835472.html", "title": "Could AbbVie Inc. (ABBV) Win as Genmab A/S (GMAB) Faces a New Regulatory Test for Epcoritamab?", "content_text": "On July 23, Genmab A/S (NASDAQ:GMAB) and AbbVie Inc. (NYSE:ABBV) clarified a key clinical setback regarding their jointly developed T-cell engaging bispecific antibody, epcoritamab (DuoBody-CD3xCD20). The Phase 3 EPCORE DLBCL-1 study evaluated epcoritamab monotherapy against investigator's choice of chemoimmunotherapy in transplant-ineligible adults with relapsed/refractory diffuse large B-cell lymphoma. The clarification confirmed that in the United States, where overall survival was the sole primary endpoint, the trial failed to demonstrate a statistically significant improvement, missing it", "date_published": "2026-08-13T23:38:35+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Regulatory and legal", "GE9"], "_sharemaestro": {"country": "Germany", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "GE9", "name": "GENMAB AS                     N", "sentiment_url": "https://sharemaestro.com/sentiment/ffbb4876-1d5e-482e-9cbc-952a406eec44/"}]}}, {"id": "source:eda8f19d1dc917fc7d6b4415772bef1bc875aab36b5a78debadc9b40f76e77e4", "url": "https://finance.yahoo.com/healthcare/articles/inside-latigo-biotherapeutics-ipo-non-133527897.html", "external_url": "https://finance.yahoo.com/healthcare/articles/inside-latigo-biotherapeutics-ipo-non-133527897.html", "title": "Inside Latigo Biotherapeutics\u2019 IPO: A Non-Opioid Pain Bet Goes Public", "content_text": "Quick Read LTGO priced its IPO at $18, opened at $21, and raised nearly $350 million from an oversubscribed offering. LTG-001 delivered 50% greater pain relief than hydrocodone in a 343-patient trial, positioning it for a first-ever opioid-free label claim. Phase 3 trials launching in 2026 with 2027 readouts will test whether Latigo's Nav1.8 pipeline can replicate Vertex's suzetrigine success. Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks \u2014 and LTGO didn't make the cut. Grab the names FREE today. Latigo Biotherapeutics (NASDAQ:LTGO) arrived on public markets wi", "date_published": "2026-08-13T13:35:27+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "VX1"], "_sharemaestro": {"country": "Germany", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "VX1", "name": "Vertex Pharmaceuticals Incorporated", "sentiment_url": "https://sharemaestro.com/sentiment/0a10da90-393d-44b4-8a20-d4e106ccaad9/"}]}}, {"id": "source:9f0fd8efdab13969c8c20c5ec2fde09c58e885cbfebfea05503d7e5fbacf6706", "url": "https://finance.yahoo.com/healthcare/articles/parabilis-medicines-reports-second-quarter-110000177.html", "external_url": "https://finance.yahoo.com/healthcare/articles/parabilis-medicines-reports-second-quarter-110000177.html", "title": "Parabilis Medicines Reports Second Quarter 2026 Financial Results and Provides Business Updates", "content_text": "Parabilis Medicines, Inc. Advanced zolucatetide across multiple Wnt/\u03b2-catenin-driven diseases, including progress toward planned Phase 3 registrational trial in desmoid tumors Announced strategic research collaboration with Regeneron to develop Antibody-Helicon Conjugates, expanding application of company's proprietary HeliconTM platform; received $125M in upfront consideration and equity investment, with the potential for up to $2.2B in milestone payments plus tiered royalties Ended the second quarter with a strong financial position with $1.1B in cash, cash equivalents and marketable securit", "date_published": "2026-08-13T11:00:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "RGO"], "_sharemaestro": {"country": "Germany", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "RGO", "name": "Regeneron Pharmaceuticals, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/cdb53169-f08e-4509-9fef-82424c1bca56/"}]}}, {"id": "source:2b01ca1fb4082ad003946edd1a168f34758796aeccf23f8dae47ea177ab294c9", "url": "https://seekingalpha.com/news/4632084-valneva-gaap-eps-of-035-revenue-of-6584m-reaffirms-fy-2026?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "external_url": "https://seekingalpha.com/news/4632084-valneva-gaap-eps-of-035-revenue-of-6584m-reaffirms-fy-2026?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "title": "Valneva GAAP EPS of -\u20ac0.35, revenue of \u20ac65.84M; reaffirms FY 2026", "content_text": "* Valneva press release [https://seekingalpha.com/pr/20617691-valneva-reports-half-year-2026-financial-results-and-provides-corporate-updates] (VALN [https://seekingalpha.com/symbol/VALN]): 1H GAAP EPS of -\u20ac0.35. * Revenue of \u20ac65.84M (-32.5% Y/Y). * Solid cash position of \u20ac121.5 million as of end June 2026. * FINANCIAL OUTLOOK * Despite the continued adverse impact of the geopolitical environment on travel, Valneva reaffirmed its 2026 guidance with expected product sales of \u20ac135 million to \u20ac150 million and total revenues of \u20ac145 million to \u20ac160 million. * Product gross margins are expected to ", "date_published": "2026-08-13T06:05:24+00:00", "authors": [{"name": "seekingalpha.com"}], "tags": ["Earnings", "AYJ"], "_sharemaestro": {"country": "Germany", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "AYJ", "name": "Valneva SE", "sentiment_url": "https://sharemaestro.com/sentiment/72be05a1-645b-4461-92f2-b776ddee3ee3/"}]}}, {"id": "source:cd43458cb731296f7072733bebb601944bde7b3165366430c94af54a3ae6c0ff", "url": "https://finance.yahoo.com/healthcare/articles/valneva-reports-half-2026-financial-050000261.html", "external_url": "https://finance.yahoo.com/healthcare/articles/valneva-reports-half-2026-financial-050000261.html", "title": "Valneva Reports Half Year 2026 Financial Results and Provides Corporate Updates", "content_text": "VALNEVA SE Total product sales of \u20ac64.0 million In-line with expectations; full-year guidance of \u20ac135 -150 million reaffirmed Solid cash position of \u20ac121.5 million as of end June 2026 Reflects disciplined cash management and proceeds from the recent reserved offering1 Restructuring program implemented with positive P&L and cash flow impacts expected in the second half of the year and beyond Regulatory decisions for Lyme disease vaccine candidate expected in the next twelve months2 Pfizer remains optimistic about obtaining registration for the vaccine candidate3 Lyon (France), August 13, 2026 \u2013", "date_published": "2026-08-13T05:00:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "AYJ"], "_sharemaestro": {"country": "Germany", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "AYJ", "name": "Valneva SE", "sentiment_url": "https://sharemaestro.com/sentiment/72be05a1-645b-4461-92f2-b776ddee3ee3/"}]}}, {"id": "source:5add507d902b319624faf3a59149580d52f5377ffbcbd17ffccbb7be57034b35", "url": "https://news.google.com/rss/articles/CBMia0FVX3lxTFBYdGFQSUc4OUJ4LTVRRURRRWVfTlFjQTNndlhzcVltX0N0cWVENmdnM2oxcVF0dzlIRlNMbmh2eTFhX3R3MkZFVFJMaldLSlZmYk4tbXFncTNOdGZfaHVmbllDMGhtdzdjdGNZ?oc=5", "external_url": "https://news.google.com/rss/articles/CBMia0FVX3lxTFBYdGFQSUc4OUJ4LTVRRURRRWVfTlFjQTNndlhzcVltX0N0cWVENmdnM2oxcVF0dzlIRlNMbmh2eTFhX3R3MkZFVFJMaldLSlZmYk4tbXFncTNOdGZfaHVmbllDMGhtdzdjdGNZ?oc=5", "title": "VERTEX PHARMACEUTICALS AKTIE: AI-Analysen, Prognose & Kursziel", "content_text": "VERTEX PHARMACEUTICALS AKTIE: AI-Analysen, Prognose & Kursziel", "date_published": "2026-08-13T00:29:11+00:00", "authors": [{"name": "finanzen.net"}], "tags": ["Market update", "VX1"], "_sharemaestro": {"country": "Germany", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "VX1", "name": "Vertex Pharmaceuticals Incorporated", "sentiment_url": "https://sharemaestro.com/sentiment/0a10da90-393d-44b4-8a20-d4e106ccaad9/"}]}}, {"id": "source:15cb90517d578b763e104c2e95c03c45b13caec26d6615a176e3914e9290a3ac", "url": "https://finance.yahoo.com/healthcare/articles/vertex-multiple-portfolio-catalysts-favorable-150252779.html", "external_url": "https://finance.yahoo.com/healthcare/articles/vertex-multiple-portfolio-catalysts-favorable-150252779.html", "title": "Vertex Has Multiple Portfolio Catalysts With Favorable Risk-Reward, RBC Says", "content_text": "Vertex Pharmaceuticals (VRTX) has multiple potential catalysts coming from its portfolio that provide a net positive risk-reward profile for the company, RBC Capital Markets said in a Wednesday note.The company is expected to present results from its phase 1 study of VX-828 in Silver Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade now", "date_published": "2026-08-12T15:02:52+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "VX1"], "_sharemaestro": {"country": "Germany", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "VX1", "name": "Vertex Pharmaceuticals Incorporated", "sentiment_url": "https://sharemaestro.com/sentiment/0a10da90-393d-44b4-8a20-d4e106ccaad9/"}]}}, {"id": "source:01fdb285f0dc5ada4e1618bd8f22616eba1e6109753c3a439aa7e8e38ef17154", "url": "https://news.google.com/rss/articles/CBMi1wFBVV95cUxPRUhvQnJZUGNfR0VKVkp3Y2tjR1FCTXZwTG5ST0tyLTJzaHpoRW1XRVRBeGd1YU5JaXQtVWN0Tk1YSk9nZFpHdV9kaElYRkdISnFITkpBankxaGF4c2xGNHdtRTZ5NDhES25OeEhHVTlIUDJWMkZXMjFBX2VqRXFpa1pQcU9aTDZMdExTSTdsbi1zR0JPby1ieG1uZUlHWFNiSi1fRE9PRlRmcW5CT2JpM0pnaktpcktDd05zaVMxcGp0ZzdSUjcwWmp5NmVRT01UbUNvZXlQYw?oc=5", "external_url": "https://news.google.com/rss/articles/CBMi1wFBVV95cUxPRUhvQnJZUGNfR0VKVkp3Y2tjR1FCTXZwTG5ST0tyLTJzaHpoRW1XRVRBeGd1YU5JaXQtVWN0Tk1YSk9nZFpHdV9kaElYRkdISnFITkpBankxaGF4c2xGNHdtRTZ5NDhES25OeEhHVTlIUDJWMkZXMjFBX2VqRXFpa1pQcU9aTDZMdExTSTdsbi1zR0JPby1ieG1uZUlHWFNiSi1fRE9PRlRmcW5CT2JpM0pnaktpcktDd05zaVMxcGp0ZzdSUjcwWmp5NmVRT01UbUNvZXlQYw?oc=5", "title": "Formycon: Umsatz im ersten Halbjahr 2026 fast verdreifacht, Verluste deutlich reduziert", "content_text": "Formycon: Umsatz im ersten Halbjahr 2026 fast verdreifacht, Verluste deutlich reduziert", "date_published": "2026-08-12T13:57:00+00:00", "authors": [{"name": "Investing.com Deutsch"}], "tags": ["Market update", "FYB"], "_sharemaestro": {"country": "Germany", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "FYB", "name": "Formycon AG", "sentiment_url": "https://sharemaestro.com/sentiment/ecf778e0-d8d5-4981-9874-3c9123d8ff80/"}]}}, {"id": "source:77c9df0ffab0dcaff3034f70e888688fbcf314006ca5b7527e8fc365cf5026bf", "url": "https://finance.yahoo.com/healthcare/articles/one-company-clinical-miss-another-034131355.html", "external_url": "https://finance.yahoo.com/healthcare/articles/one-company-clinical-miss-another-034131355.html", "title": "One Company\u2019s Clinical Miss Is Another\u2019s Moat: Vertex Rallies as Sionna\u2019s CF Bet Collapses", "content_text": "Cystic fibrosis investors came to learn a harsh lesson on August 10 about how concentrated a market can be: Sionna Therapeutics, Inc. (NASDAQ:SION) shares fell more than 90% following a key trial failure, while Vertex Pharmaceuticals (NASDAQ:VRTX), the company whose drug dominance Sionna was attempting to challenge, surged to new highs. The Pipeline Flop Sionna Therapeutics, Inc. (NASDAQ:SION) announced the topline results of its Phase 2a \"PreciSION CF\" trial the morning of August 10, which tested its lead drug candidate SION-719 as a complementary therapy to Vertex's blockbuster Trikafta regi", "date_published": "2026-08-12T03:41:31+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "VX1"], "_sharemaestro": {"country": "Germany", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "VX1", "name": "Vertex Pharmaceuticals Incorporated", "sentiment_url": "https://sharemaestro.com/sentiment/0a10da90-393d-44b4-8a20-d4e106ccaad9/"}]}}, {"id": "source:55a3270eab70bcb7bf8317e3b4c68cd08419056da1e9e96c4e285557febdbf61", "url": "https://finance.yahoo.com/healthcare/articles/5-insightful-analyst-questions-vertex-014122962.html", "external_url": "https://finance.yahoo.com/healthcare/articles/5-insightful-analyst-questions-vertex-014122962.html", "title": "5 Insightful Analyst Questions From Vertex Pharmaceuticals\u2019s Q2 Earnings Call", "content_text": "5 Insightful Analyst Questions From Vertex Pharmaceuticals's Q2 Earnings Call Vertex Pharmaceuticals' second quarter reflected strong commercial momentum, with management highlighting the performance of its cystic fibrosis (CF) portfolio and accelerating uptake of newer products like CASGEVY and JOURNAVX. CEO Reshma Kewalramani attributed revenue growth to \"the strength of our cystic fibrosis portfolio and the growing contributions from our newer products,\" while also emphasizing progress in regulatory and clinical milestones. Management specifically noted that ALYFTREK and TRIKAFTA continued ", "date_published": "2026-08-12T01:41:22+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "VX1"], "_sharemaestro": {"country": "Germany", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "VX1", "name": "Vertex Pharmaceuticals Incorporated", "sentiment_url": "https://sharemaestro.com/sentiment/0a10da90-393d-44b4-8a20-d4e106ccaad9/"}]}}, {"id": "source:e6b8fb8b7756e99aa4374c23943f6e0a9e8a1e41130e8092aada209c9a6372c1", "url": "https://finance.yahoo.com/markets/stocks/articles/capital-increase-genmab-result-employee-175300211.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/capital-increase-genmab-result-employee-175300211.html", "title": "Capital Increase in Genmab as a Result of Employee Warrant Exercise", "content_text": "Genmab A/S Company Announcement COPENHAGEN, Denmark; August 11, 2026 \u2013 Genmab A/S (Nasdaq: GMAB) will increase its share capital by 24,592 shares as a consequence of the exercise of employee warrants. The increase is effected without any preemption rights for the existing shareholders of the Company or others. The shares are subscribed in cash at the following price per share of nominally DKK 1: 4,702 shares at DKK 1,334.50, 2,069 shares at DKK 1,362.50, and 17,821 shares at DKK 1,615.00. Proceeds to the Company are approximately DKK 37.9 million. The increase corresponds to approximately 0.04", "date_published": "2026-08-11T17:53:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Capital return", "GE9"], "_sharemaestro": {"country": "Germany", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "GE9", "name": "GENMAB AS                     N", "sentiment_url": "https://sharemaestro.com/sentiment/ffbb4876-1d5e-482e-9cbc-952a406eec44/"}]}}, {"id": "source:307c68c8377bcf013ad783581ce907b734df56f45e0558685346ed0bf0510ade", "url": "https://finance.yahoo.com/healthcare/articles/regn-soars-21-9-month-143000494.html", "external_url": "https://finance.yahoo.com/healthcare/articles/regn-soars-21-9-month-143000494.html", "title": "REGN Soars 21.9% in a Month: Buy, Sell or Hold the Stock?", "content_text": "The going has been strong for Regeneron Pharmaceuticals REGN over the past month. Shares of this biotech giant have surged 21.9% over the said time frame, outpacing the industry's growth of 4%. The stock has also outperformed the sector and the S&P 500 Index during this time. REGN's robust rally has been driven by better-than-expected quarterly results, which can be attributed to robust demand for Eylea HD (higher dose of Eylea) and higher profit-sharing from Dupixent that helped the company mitigate the decline in Eylea sales. REGN Outperforms Industry, Sector and S&P 500 IndexZacks Investmen", "date_published": "2026-08-11T14:30:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "RGO"], "_sharemaestro": {"country": "Germany", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "RGO", "name": "Regeneron Pharmaceuticals, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/cdb53169-f08e-4509-9fef-82424c1bca56/"}]}}, {"id": "source:2c9b34f675f32164fc8735ca0b8098e9fef6cdde23b1629a77015a7807e8d04c", "url": "https://finance.yahoo.com/healthcare/articles/4-biotech-stocks-major-second-140100024.html", "external_url": "https://finance.yahoo.com/healthcare/articles/4-biotech-stocks-major-second-140100024.html", "title": "4 Biotech Stocks With Major Second-Half Pipeline Catalysts This Year", "content_text": "The pharmaceutical sector differs from many industries as stock performance often depends less on near-term results and more on the success of products in development. For biotech companies, clinical and regulatory developments can sharply alter valuations by changing expectations for a drug's safety, efficacy and commercial potential. Pipeline milestones are therefore key stock catalysts. Clinical data can validate or undermine a candidate, while regulatory decisions can bring it closer to commercialization. Late-stage data and regulatory milestones generally have a significant impact on stoc", "date_published": "2026-08-11T14:01:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "VX1"], "_sharemaestro": {"country": "Germany", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "VX1", "name": "Vertex Pharmaceuticals Incorporated", "sentiment_url": "https://sharemaestro.com/sentiment/0a10da90-393d-44b4-8a20-d4e106ccaad9/"}]}}, {"id": "source:97892a168b4b92de79de4914a8d03c375edaec8307765b19895be152e4b57a2c", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxQUzV4ZG1vbTQ1djdnNmMwM1dIMHZpY1pqUE9WNkd6TTBwOWw4Y3gtN1Jrc25QYlNpMGNwLUUxMlhCT0lHcFBIak1ZM19oZ256OXBxQlBEQXVjeDF2VUZRTE1UY0IyV2xJdnF5eTZjLTdyM3NHNklLZlZuZUxyYkM2SEppcW1zT3FfTzVZNUF2ZFhSRURXWjFyOTRPVnZXOTdRRkJXbnhDcw?oc=5", "external_url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxQUzV4ZG1vbTQ1djdnNmMwM1dIMHZpY1pqUE9WNkd6TTBwOWw4Y3gtN1Jrc25QYlNpMGNwLUUxMlhCT0lHcFBIak1ZM19oZ256OXBxQlBEQXVjeDF2VUZRTE1UY0IyV2xJdnF5eTZjLTdyM3NHNklLZlZuZUxyYkM2SEppcW1zT3FfTzVZNUF2ZFhSRURXWjFyOTRPVnZXOTdRRkJXbnhDcw?oc=5", "title": "Vertex Pharmaceuticals Rose 7% Today. Here\u2019s Where the Stock Is Headed in 2026", "content_text": "Vertex Pharmaceuticals Rose 7% Today. Here\u2019s Where the Stock Is Headed in 2026", "date_published": "2026-08-11T02:13:50+00:00", "authors": [{"name": "TIKR.com"}], "tags": ["Market update", "VX1"], "_sharemaestro": {"country": "Germany", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "VX1", "name": "Vertex Pharmaceuticals Incorporated", "sentiment_url": "https://sharemaestro.com/sentiment/0a10da90-393d-44b4-8a20-d4e106ccaad9/"}]}}, {"id": "source:d76c6573caaf33a4540310495d2a64dece8f7b7d3633b25c5b87a2529c2af6b0", "url": "https://finance.yahoo.com/m/b81755ac-36bf-3983-868f-dada13133338/why-sionna-therapeutics-stock.html", "external_url": "https://finance.yahoo.com/m/b81755ac-36bf-3983-868f-dada13133338/why-sionna-therapeutics-stock.html", "title": "Why Sionna Therapeutics Stock Is Crashing 92% to a Record Low", "content_text": "The biotech says its cystic fibrosis drug candidate missed the mark in a Phase 2a trial, though the news could be a boon to shares of Vertex Pharmaceuticals. Continue Reading", "date_published": "2026-08-10T16:01:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "VX1"], "_sharemaestro": {"country": "Germany", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "VX1", "name": "Vertex Pharmaceuticals Incorporated", "sentiment_url": "https://sharemaestro.com/sentiment/0a10da90-393d-44b4-8a20-d4e106ccaad9/"}]}}, {"id": "source:205b512e8b0ffa6bb8920650c9ec23803fc8fef84bfcc769bbff60e8e4060989", "url": "https://finance.yahoo.com/markets/stocks/articles/vertex-stock-jumps-5-9-155537840.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/vertex-stock-jumps-5-9-155537840.html", "title": "Vertex Stock Jumps 5.9% as Rival Cystic Fibrosis Drug Fails", "content_text": "This article first appeared on GuruFocus. Vertex Pharmaceuticals (NASDAQ:VRTX), the biotech king of cystic fibrosis, jumped approximately 5.9% in Monday's regular session after a rival drug stumbled. Sionna Therapeutics said SION-719 missed the key activity endpoint in a Phase 2a trial when added to the current standard of care. Sionna is now dropping that specific add-on strategy. That is a clean win for Vertex without Vertex doing anything. One potential challenger just lost momentum, giving its enormously profitable cystic-fibrosis franchise more breathing room. Warning! GuruFocus has detec", "date_published": "2026-08-10T15:55:37+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "VX1"], "_sharemaestro": {"country": "Germany", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "VX1", "name": "Vertex Pharmaceuticals Incorporated", "sentiment_url": "https://sharemaestro.com/sentiment/0a10da90-393d-44b4-8a20-d4e106ccaad9/"}]}}, {"id": "source:49be457c5beb197e8d56542c3cc33dd3537637da1ecb5fca8475f9aed49cd3d5", "url": "https://finance.yahoo.com/healthcare/articles/vertex-pharmaceuticals-vrtx-5-4-151413527.html", "external_url": "https://finance.yahoo.com/healthcare/articles/vertex-pharmaceuticals-vrtx-5-4-151413527.html", "title": "Vertex Pharmaceuticals (VRTX) Is Up 5.4% After Raising 2026 Revenue Guidance And Expanding Its Pipeline - Has The Bull Case Changed?", "content_text": "Vertex Pharmaceuticals recently reported second-quarter 2026 results, with revenue rising to US$3,333.9 million and net income reaching US$1,099.8 million, and raised its full-year 2026 revenue guidance to US$13.10\u2013US$13.20 billion. At the same time, a new collaboration with AbCellera on multispecific T\u2011cell engagers and a setback for a key cystic fibrosis competitor together highlight Vertex's efforts to broaden its pipeline while easing pressure on its core franchise. We'll now examine how Vertex's upgraded 2026 revenue guidance reshapes its existing investment narrative and the way investor", "date_published": "2026-08-10T15:14:13+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "VX1"], "_sharemaestro": {"country": "Germany", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "VX1", "name": "Vertex Pharmaceuticals Incorporated", "sentiment_url": "https://sharemaestro.com/sentiment/0a10da90-393d-44b4-8a20-d4e106ccaad9/"}]}}, {"id": "source:d4a997611e99bc446034b28dc1f70a02e93aa3566bb24736a84a8d5453cff49e", "url": "https://finance.yahoo.com/m/228d5141-325a-32e3-b4da-3b347a2a5268/this-biotech%E2%80%99s-drug-could.html", "external_url": "https://finance.yahoo.com/m/228d5141-325a-32e3-b4da-3b347a2a5268/this-biotech%E2%80%99s-drug-could.html", "title": "This Biotech\u2019s Drug Could Treat Hot Flashes. The Stock Is Up 36% on Good News.", "content_text": "New data show a single dose of AbCellera\u2019s menopause treatment, ABCL635, reduces how often patients with menopause experience hot flashes. Continue Reading", "date_published": "2026-08-10T14:12:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "VX1"], "_sharemaestro": {"country": "Germany", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "VX1", "name": "Vertex Pharmaceuticals Incorporated", "sentiment_url": "https://sharemaestro.com/sentiment/0a10da90-393d-44b4-8a20-d4e106ccaad9/"}]}}, {"id": "source:465ba5a146eca7a17a9dddf98eb6236a85e588fd980e3cb89e4d06168ca9fb03", "url": "https://finance.yahoo.com/m/5448cf60-d94a-347d-90d3-c5b2cd4f502f/why-vertex-pharma-popped%2C-as.html", "external_url": "https://finance.yahoo.com/m/5448cf60-d94a-347d-90d3-c5b2cd4f502f/why-vertex-pharma-popped%2C-as.html", "title": "Why Vertex Pharma Popped, As A Key Rival Plummeted 90%", "content_text": "Vertex stock surged Monday after its competitor, Sionna Therapeutics, missed the mark for its highly anticipated cystic fibrosis treatment. Continue Reading", "date_published": "2026-08-10T13:22:53+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "VX1"], "_sharemaestro": {"country": "Germany", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "VX1", "name": "Vertex Pharmaceuticals Incorporated", "sentiment_url": "https://sharemaestro.com/sentiment/0a10da90-393d-44b4-8a20-d4e106ccaad9/"}]}}, {"id": "source:d68b0a1d48719cb431f473b25ba4d707fa326d03aa64ef0c19ecde50c7fe852e", "url": "https://www.globenewswire.com/news-release/2026/08/09/3341497/9788/en/bronstein-gewirtz-grossman-llc-urges-regeneron-pharmaceuticals-inc-investors-to-act-class-action-filed-alleging-investor-harm.html", "external_url": "https://www.globenewswire.com/news-release/2026/08/09/3341497/9788/en/bronstein-gewirtz-grossman-llc-urges-regeneron-pharmaceuticals-inc-investors-to-act-class-action-filed-alleging-investor-harm.html", "title": "Bronstein, Gewirtz & Grossman LLC Urges Regeneron Pharmaceuticals, Inc. Investors to Act: Class Action Filed Alleging Investor Harm", "content_text": "NEW YORK, Aug. 09, 2026 (GLOBE NEWSWIRE) -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and certain of its officers. This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Regeneron securities between August 1, 2025 and May 15, 2026, both dates inclusive (the \u201cClass Period\u201d). Such investors are encouraged to join this", "date_published": "2026-08-09T16:00:00+00:00", "authors": [{"name": "globenewswire.com"}], "tags": ["Regulatory and legal", "RGO"], "_sharemaestro": {"country": "Germany", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "RGO", "name": "Regeneron Pharmaceuticals, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/cdb53169-f08e-4509-9fef-82424c1bca56/"}]}}, {"id": "source:ab7ac04926cd9740280faa7177e2c8f0ac3ed5137926972b8cdeb4cac2b6bc92", "url": "https://news.google.com/rss/articles/CBMiakFVX3lxTE80cTMxdFdHQVRzMmo5U0NDVDE0YnhZUUs5Q0FLLUJzd2s4clYya1g1azQzMTNpekN2SG9BMm1PbjdYb1RsU0loZHpXWHBZMDhKcGd3cHp5YlRrNW5jV1ZBVGhqaGx1U3hDb1E?oc=5", "external_url": "https://news.google.com/rss/articles/CBMiakFVX3lxTE80cTMxdFdHQVRzMmo5U0NDVDE0YnhZUUs5Q0FLLUJzd2s4clYya1g1azQzMTNpekN2SG9BMm1PbjdYb1RsU0loZHpXWHBZMDhKcGd3cHp5YlRrNW5jV1ZBVGhqaGx1U3hDb1E?oc=5", "title": "Regeneron Pharmaceuticals Inc (REGN) Gewinnprognose: Zuk\u00fcnftige EPS & Umsatzwachstumsprognosen", "content_text": "Regeneron Pharmaceuticals Inc (REGN) Gewinnprognose: Zuk\u00fcnftige EPS & Umsatzwachstumsprognosen", "date_published": "2026-08-09T07:00:00+00:00", "authors": [{"name": "TradingKey"}], "tags": ["Earnings", "RGO"], "_sharemaestro": {"country": "Germany", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "RGO", "name": "Regeneron Pharmaceuticals, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/cdb53169-f08e-4509-9fef-82424c1bca56/"}]}}, {"id": "source:2668ba56fc8490dfdf15ee7d2ca8fb74a8b9a2a4ea525fbefdc9b370d1a7b91c", "url": "https://finance.yahoo.com/markets/stocks/articles/regeneron-pharmaceuticals-regn-keeps-buybacks-231155132.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/regeneron-pharmaceuticals-regn-keeps-buybacks-231155132.html", "title": "Regeneron Pharmaceuticals (REGN) Keeps Buybacks And Dividend In Focus As Fair Value Stays In Sight", "content_text": "Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Dividend, earnings and buybacks in focus Regeneron Pharmaceuticals (REGN) has given investors several fresh data points to consider after confirming a quarterly dividend, releasing second quarter and half year 2026 results, and updating on recent share repurchases. See our latest analysis for Regeneron Pharmaceuticals. Alongside the latest dividend and earnings update, Regeneron Pharmaceuticals' recent share price return of 18.33% over 30 days and 9.72% over 90 days suggests ", "date_published": "2026-08-08T23:11:55+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "RGO"], "_sharemaestro": {"country": "Germany", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "RGO", "name": "Regeneron Pharmaceuticals, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/cdb53169-f08e-4509-9fef-82424c1bca56/"}]}}, {"id": "source:fd6f6ddc120c4d3f8b5e3d484fa6bed2d394475902a0ec5eeeefda565db16bfa", "url": "https://seekingalpha.com/news/4629652-sa-asks-whats-the-outlook-for-big-pharma-ma?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "external_url": "https://seekingalpha.com/news/4629652-sa-asks-whats-the-outlook-for-big-pharma-ma?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "title": "SA Asks: What's the outlook for Big Pharma M&A?", "content_text": "[Medical research with pipette and test tube, DNA analysis, biotechnology, genetic science and healthcare] jittawit.21 Big Pharma moved back into the spotlight last week following a Financial Times report that Bristol Myers Squibb (BMY [https://seekingalpha.com/symbol/BMY]) was in merger talks with AstraZeneca (AZN [https://seekingalpha.com/symbol/AZN]), a development that was later denied by unnamed sources to Reuters. We asked Seeking Alpha analysts Stephen Ayers [https://seekingalpha.com/author/stephen-ayers], ALLKA Research [https://seekingalpha.com/author/allka-research], and Chris DeMuth", "date_published": "2026-08-08T19:28:35+00:00", "authors": [{"name": "seekingalpha.com"}], "tags": ["Deals and strategy", "RGO"], "_sharemaestro": {"country": "Germany", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "RGO", "name": "Regeneron Pharmaceuticals, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/cdb53169-f08e-4509-9fef-82424c1bca56/"}]}}, {"id": "source:eec75b916e78d13e1aeb0e953ce1b12e808fcc907458f7cf34490e1ddba98873", "url": "https://seekingalpha.com/news/4629325-earnings-scorecard-95-healthcare-firm-deliver-eps-wins-this-week?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "external_url": "https://seekingalpha.com/news/4629325-earnings-scorecard-95-healthcare-firm-deliver-eps-wins-this-week?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "title": "Earnings Scorecard: 95% of healthcare firms deliver EPS wins this week", "content_text": "Major healthcare heavyweights, including Pfizer (PFE [https://seekingalpha.com/symbol/PFE]), Merck (MRK [https://seekingalpha.com/symbol/MRK]), and Eli Lilly (LLY [https://seekingalpha.com/symbol/LLY]), reported their quarterly earnings this week, pushing the healthcare sector into positive territory after five consecutive sessions of losses. The State Street Health Care Select Sector SPDR ETF [https://seekingalpha.com/symbol/XLV] (XLV [https://seekingalpha.com/symbol/XLV]) rose 1.36% in the week so far. On a YTD basis, XLV has added more than 5%; however, it is lagging behind the broader S&P ", "date_published": "2026-08-08T15:15:33+00:00", "authors": [{"name": "seekingalpha.com"}], "tags": ["Earnings", "VX1"], "_sharemaestro": {"country": "Germany", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "VX1", "name": "Vertex Pharmaceuticals Incorporated", "sentiment_url": "https://sharemaestro.com/sentiment/0a10da90-393d-44b4-8a20-d4e106ccaad9/"}]}}, {"id": "source:1375ddeac495f4e50502b2ba50a6769b68d3d64bda93776ebc4a98e54434432a", "url": "https://news.google.com/rss/articles/CBMiakFVX3lxTFA3bUdHbzdDcEltNFhKTjZXTWM0cXdMdFI1UEppYmgtcnh5eU5sUi1KU2Q1ekV4cHljUlJ2c084b2ZobUI1VjQ4VURCc1J1RDlReEtES3V4cWpyV0QxUnhhZENENkZDN2xSNkE?oc=5", "external_url": "https://news.google.com/rss/articles/CBMiakFVX3lxTFA3bUdHbzdDcEltNFhKTjZXTWM0cXdMdFI1UEppYmgtcnh5eU5sUi1KU2Q1ekV4cHljUlJ2c084b2ZobUI1VjQ4VURCc1J1RDlReEtES3V4cWpyV0QxUnhhZENENkZDN2xSNkE?oc=5", "title": "Valneva SE (VALN) Gewinnprognose: Zuk\u00fcnftige EPS & Umsatzwachstumsprognosen", "content_text": "Valneva SE (VALN) Gewinnprognose: Zuk\u00fcnftige EPS & Umsatzwachstumsprognosen", "date_published": "2026-08-06T07:00:00+00:00", "authors": [{"name": "TradingKey"}], "tags": ["Earnings", "AYJ"], "_sharemaestro": {"country": "Germany", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "AYJ", "name": "Valneva SE", "sentiment_url": "https://sharemaestro.com/sentiment/72be05a1-645b-4461-92f2-b776ddee3ee3/"}]}}, {"id": "source:0ea486579ca410335d4175061659c7aae345f36399ddf0d6e0349f66c4f05e8b", "url": "https://news.google.com/rss/articles/CBMizgFBVV95cUxPZXVjdVlWMW9hTlR4WUFrQm1yX3M3clZWU0xidmNBSHVGREllcXdGUUtmY1BFVmozLW5MLVVZYjM4TFR0ZFdWSkVua3pjOW9VcnFGbDRQQ3RUcWg2d2pPRTNSeDlBdkh3a05tV0ZlN3ZFYlVhVC03QnEyd0dTdU9zR0hZaUtVVU1SWkZWU3VYZ29fTDJxcFRrWXJXSVEzRmxldnp2eFdrYnNFMjljclRMWGZsWThUNGZiVXRYbUF4V1lNWE5DWkJac2xzMTR2UQ?oc=5", "external_url": "https://news.google.com/rss/articles/CBMizgFBVV95cUxPZXVjdVlWMW9hTlR4WUFrQm1yX3M3clZWU0xidmNBSHVGREllcXdGUUtmY1BFVmozLW5MLVVZYjM4TFR0ZFdWSkVua3pjOW9VcnFGbDRQQ3RUcWg2d2pPRTNSeDlBdkh3a05tV0ZlN3ZFYlVhVC03QnEyd0dTdU9zR0hZaUtVVU1SWkZWU3VYZ29fTDJxcFRrWXJXSVEzRmxldnp2eFdrYnNFMjljclRMWGZsWThUNGZiVXRYbUF4V1lNWE5DWkJac2xzMTR2UQ?oc=5", "title": "Vertex Pharmaceuticals\u2019 Q2 Earnings Call Confirmed an $8.8 Billion Bet. Here\u2019s What That Means for the Stock", "content_text": "Vertex Pharmaceuticals\u2019 Q2 Earnings Call Confirmed an $8.8 Billion Bet. Here\u2019s What That Means for the Stock", "date_published": "2026-08-04T07:00:00+00:00", "authors": [{"name": "TIKR.com"}], "tags": ["Earnings", "VX1"], "_sharemaestro": {"country": "Germany", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "VX1", "name": "Vertex Pharmaceuticals Incorporated", "sentiment_url": "https://sharemaestro.com/sentiment/0a10da90-393d-44b4-8a20-d4e106ccaad9/"}]}}, {"id": "source:24f6c150c539ec54105e29a78d44e44dc353417388094dff30aa640fcf4cd7a0", "url": "https://news.google.com/rss/articles/CBMi4wFBVV95cUxQWnNCeF9yRThRXzE2Yk1RWko1V213cFFQNlAtQkYtZ3Q2cnVDSjE1Y3pCWktHalhMOTZPaGNpSjlBVW4wbnl3N3BwSWo5N09fUHcxeHBobVZtX1liaU5lckx6YjFwUF9WbzJBNHFqTkpsbXZJVUJmMHdGLTA0eEhsR3dkREtUcXZzeGlSZ2JQVUhEVlBvV1BnQ01uczZ4QkQzRERodUlxZmRCOVoySmFWbmdUUVVPSHhGTHB4aVVQa242WEdZZ1Y5dW9sTWhVVmEyN3h2Y09JRDNtV1Y5YXFkVC1EMA?oc=5", "external_url": "https://news.google.com/rss/articles/CBMi4wFBVV95cUxQWnNCeF9yRThRXzE2Yk1RWko1V213cFFQNlAtQkYtZ3Q2cnVDSjE1Y3pCWktHalhMOTZPaGNpSjlBVW4wbnl3N3BwSWo5N09fUHcxeHBobVZtX1liaU5lckx6YjFwUF9WbzJBNHFqTkpsbXZJVUJmMHdGLTA0eEhsR3dkREtUcXZzeGlSZ2JQVUhEVlBvV1BnQ01uczZ4QkQzRERodUlxZmRCOVoySmFWbmdUUVVPSHhGTHB4aVVQa242WEdZZ1Y5dW9sTWhVVmEyN3h2Y09JRDNtV1Y5YXFkVC1EMA?oc=5", "title": "Vertex Pharmaceuticals Incorporated erh\u00f6ht Gewinnprognose f\u00fcr das Gesamtjahr 2026", "content_text": "Vertex Pharmaceuticals Incorporated erh\u00f6ht Gewinnprognose f\u00fcr das Gesamtjahr 2026", "date_published": "2026-08-03T20:01:00+00:00", "authors": [{"name": "MarketScreener Deutschland"}], "tags": ["Market update", "VX1"], "_sharemaestro": {"country": "Germany", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "VX1", "name": "Vertex Pharmaceuticals Incorporated", "sentiment_url": "https://sharemaestro.com/sentiment/0a10da90-393d-44b4-8a20-d4e106ccaad9/"}]}}, {"id": "source:1d29688831fa1e64fb463afa681c7ed39abaecea1f1df301e212c206052714ea", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxOc0x0blVabnQ1enRRX25oRnZLb3d4M0puZEsxMlh6LVFNOFI4YlotT2RycmhBSjJqTEVwS2lMS0JEN21lNEZCaWZUZUJEcktCcUxsZWJma2duai1HNWdrZGVBVC1ST1cwdzhHLVY0bDNhanhXNXZvbXMzU2VFci1GMFpNT0RWY0U2Ymt0dXVZX3oxX3dlY1gxSlBqTDJpN0dh?oc=5", "external_url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxOc0x0blVabnQ1enRRX25oRnZLb3d4M0puZEsxMlh6LVFNOFI4YlotT2RycmhBSjJqTEVwS2lMS0JEN21lNEZCaWZUZUJEcktCcUxsZWJma2duai1HNWdrZGVBVC1ST1cwdzhHLVY0bDNhanhXNXZvbXMzU2VFci1GMFpNT0RWY0U2Ymt0dXVZX3oxX3dlY1gxSlBqTDJpN0dh?oc=5", "title": "Regeneron Pharma Q2 Earnings: EYLEA HD Outsold EYLEA for the First Time", "content_text": "Regeneron Pharma Q2 Earnings: EYLEA HD Outsold EYLEA for the First Time", "date_published": "2026-08-03T07:00:00+00:00", "authors": [{"name": "TIKR.com"}], "tags": ["Earnings", "RGO"], "_sharemaestro": {"country": "Germany", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "RGO", "name": "Regeneron Pharmaceuticals, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/cdb53169-f08e-4509-9fef-82424c1bca56/"}]}}, {"id": "source:9749d6203936619c7bc21f5ef3e06d403a43f700def82f3969319e5e3de3487d", "url": "https://news.google.com/rss/articles/CBMi9wFBVV95cUxQYkRxbkJNTTFUOU1nZDh3RXY2VDNnN3dMbUlTUWxVeU1OdlJOdjI0QjVBdjJSRGh2bTdKWFFxSndvcjd5eS1ISnZVTDlERkxJdnk2NGVUOU54WC13UVdlQmpzd2hsVjNzRFFpS1l5OXB2MW5ZR2daUTVwX1lYNkRmbmhUZE41aWxWMnBiclNyZWNiMVZ6RFpkeFJtM2o5ZXBvejR5M1ZGNkNxYUhTWjFWSDVKMzdMTjYxMlBMem1jS3FlblNWcGttNDgtNEtOZDFtT2tidk1abzBEdlVtLTdfUjZrSXkxRnNVSjVnREZuSTg0a1VnNnVr?oc=5", "external_url": "https://news.google.com/rss/articles/CBMi9wFBVV95cUxQYkRxbkJNTTFUOU1nZDh3RXY2VDNnN3dMbUlTUWxVeU1OdlJOdjI0QjVBdjJSRGh2bTdKWFFxSndvcjd5eS1ISnZVTDlERkxJdnk2NGVUOU54WC13UVdlQmpzd2hsVjNzRFFpS1l5OXB2MW5ZR2daUTVwX1lYNkRmbmhUZE41aWxWMnBiclNyZWNiMVZ6RFpkeFJtM2o5ZXBvejR5M1ZGNkNxYUhTWjFWSDVKMzdMTjYxMlBMem1jS3FlblNWcGttNDgtNEtOZDFtT2tidk1abzBEdlVtLTdfUjZrSXkxRnNVSjVnREZuSTg0a1VnNnVr?oc=5", "title": "Vertex Pharmaceuticals: Bereinigter Gewinn und Umsatz im 2. Quartal steigen; Prognose f\u00fcr 2026 angehoben", "content_text": "Vertex Pharmaceuticals: Bereinigter Gewinn und Umsatz im 2. Quartal steigen; Prognose f\u00fcr 2026 angehoben", "date_published": "2026-08-03T07:00:00+00:00", "authors": [{"name": "MarketScreener Deutschland"}], "tags": ["Market update", "VX1"], "_sharemaestro": {"country": "Germany", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "VX1", "name": "Vertex Pharmaceuticals Incorporated", "sentiment_url": "https://sharemaestro.com/sentiment/0a10da90-393d-44b4-8a20-d4e106ccaad9/"}]}}, {"id": "source:8c64dd933537b0f034e39466f2f83ea8ac9bc2d68ca98d5c4710901bb3aa8104", "url": "https://news.google.com/rss/articles/CBMiXkFVX3lxTE5aUkxGZ1dnTEZxTUMtNjJkUTR3SXg5S05xSmkzYURVb05obHJvY2YtYmdVZFJPaGY4UXJXcVZCa0FlMkxMX2VPZzJTNGVGVm9rZWViOG5Ybm5ISXdHRVE?oc=5", "external_url": "https://news.google.com/rss/articles/CBMiXkFVX3lxTE5aUkxGZ1dnTEZxTUMtNjJkUTR3SXg5S05xSmkzYURVb05obHJvY2YtYmdVZFJPaGY4UXJXcVZCa0FlMkxMX2VPZzJTNGVGVm9rZWViOG5Ybm5ISXdHRVE?oc=5", "title": "VRTX|Vertex Pharmaceuticals Inc|Kurs:496.070|\u00c4nderung %:+12.040", "content_text": "VRTX|Vertex Pharmaceuticals Inc|Kurs:496.070|\u00c4nderung %:+12.040", "date_published": "2026-08-03T07:00:00+00:00", "authors": [{"name": "TradingKey"}], "tags": ["Market update", "VX1"], "_sharemaestro": {"country": "Germany", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "VX1", "name": "Vertex Pharmaceuticals Incorporated", "sentiment_url": "https://sharemaestro.com/sentiment/0a10da90-393d-44b4-8a20-d4e106ccaad9/"}]}}, {"id": "source:72349cde7e39827c3c2049ce677168b1d6e39552c82c63218539b039af9aacd1", "url": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxNM1JLVGhvU2Rzb2JMWElKLUFjaXVObENXa0Y3U2t1RUxZajNyX0FMQWpINUlsU3Q3NFFCSnJORFpSZlRnUlNFM3FyX3hUTy1XWTBGbDk3cnozblJSZ1Z1Wmo5WUI0U3l1U1ZkUEM5YnY4Mkd4UldlYVhQU1UzaDQ2alFpUlZackthMm1SY2FuQ1hUZlNOMnRYXzZ4WlJ4OFBsS3Y2OVRhd2FjcXU3UENUdm5wcXR0R1MxMC04QnZGczFuSUU?oc=5", "external_url": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxNM1JLVGhvU2Rzb2JMWElKLUFjaXVObENXa0Y3U2t1RUxZajNyX0FMQWpINUlsU3Q3NFFCSnJORFpSZlRnUlNFM3FyX3hUTy1XWTBGbDk3cnozblJSZ1Z1Wmo5WUI0U3l1U1ZkUEM5YnY4Mkd4UldlYVhQU1UzaDQ2alFpUlZackthMm1SY2FuQ1hUZlNOMnRYXzZ4WlJ4OFBsS3Y2OVRhd2FjcXU3UENUdm5wcXR0R1MxMC04QnZGczFuSUU?oc=5", "title": "Vertex hebt FY26-Umsatzprognose nach Q2-Ergebnis: Crinetics-Deal, ALYF", "content_text": "Vertex hebt FY26-Umsatzprognose nach Q2-Ergebnis: Crinetics-Deal, ALYF", "date_published": "2026-08-03T07:00:00+00:00", "authors": [{"name": "Goldesel.de"}], "tags": ["Market update", "VX1"], "_sharemaestro": {"country": "Germany", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "VX1", "name": "Vertex Pharmaceuticals Incorporated", "sentiment_url": "https://sharemaestro.com/sentiment/0a10da90-393d-44b4-8a20-d4e106ccaad9/"}]}}, {"id": "source:f4903260ddd5a59d895dec165107e10404188e5d445749b2ac383000c98bb0c4", "url": "https://news.google.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?oc=5", "external_url": "https://news.google.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?oc=5", "title": "Die Allianz zwischen Vertex und AbCellera im Bereich T-Zell-Engager k\u00f6nnte die Argumente f\u00fcr eine Investition in Vertex Pharmaceuticals (VRTX) ver\u00e4ndern", "content_text": "Die Allianz zwischen Vertex und AbCellera im Bereich T-Zell-Engager k\u00f6nnte die Argumente f\u00fcr eine Investition in Vertex Pharmaceuticals (VRTX) ver\u00e4ndern", "date_published": "2026-07-31T07:00:00+00:00", "authors": [{"name": "simplywall.st"}], "tags": ["Market update", "VX1"], "_sharemaestro": {"country": "Germany", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "VX1", "name": "Vertex Pharmaceuticals Incorporated", "sentiment_url": "https://sharemaestro.com/sentiment/0a10da90-393d-44b4-8a20-d4e106ccaad9/"}]}}, {"id": "source:55f87a336f5d5229ce7201ff0fc9617aca641736dc93e6844c6d5a8a45a1df81", "url": "https://news.google.com/rss/articles/CBMifEFVX3lxTE9mcjhTd3ZhTUlRTFhkUFMwSDVsX0F2N0o2ZC1VeXZ5bEQwN25NOGxPb242UzdUVWZaQnN6TnVzbWREMGJocU5weElaYVkybFhHLUVabzFGMGg5M0tiamVkd1lyaE5KRG93bDZ2ZmJvYVJ2WUwzOXhRbVktdHrSAYIBQVVfeXFMTzVXbnFKOVVKTjZmSFBkS3JKVmFqaU1UZEdMaFloZGVYWVJtaXpQZFIyRVEtaTB4WFV4aF8tOV9tamxvY3M4eDVCdUpmYWxBczItcTZQay1kdE1KT0V6OUJhbFYxN1A1NUtpdGNDa0p2RlJVMmhQWGtsdFVTUndueXVoZw?oc=5", "external_url": "https://news.google.com/rss/articles/CBMifEFVX3lxTE9mcjhTd3ZhTUlRTFhkUFMwSDVsX0F2N0o2ZC1VeXZ5bEQwN25NOGxPb242UzdUVWZaQnN6TnVzbWREMGJocU5weElaYVkybFhHLUVabzFGMGg5M0tiamVkd1lyaE5KRG93bDZ2ZmJvYVJ2WUwzOXhRbVktdHrSAYIBQVVfeXFMTzVXbnFKOVVKTjZmSFBkS3JKVmFqaU1UZEdMaFloZGVYWVJtaXpQZFIyRVEtaTB4WFV4aF8tOV9tamxvY3M4eDVCdUpmYWxBczItcTZQay1kdE1KT0V6OUJhbFYxN1A1NUtpdGNDa0p2RlJVMmhQWGtsdFVTUndueXVoZw?oc=5", "title": "Heidelberg Pharma verringert Halbjahresverlust - finanziert bis Mitte 2027", "content_text": "Heidelberg Pharma verringert Halbjahresverlust - finanziert bis Mitte 2027", "date_published": "2026-07-15T08:02:39+00:00", "authors": [{"name": "4investors.de"}], "tags": ["Market update", "HPHA"], "_sharemaestro": {"country": "Germany", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "HPHA", "name": "Heidelberg Pharma AG", "sentiment_url": "https://sharemaestro.com/sentiment/db29aa2b-d482-4579-a168-33a8e9531f1b/"}]}}, {"id": "source:edbfa6d56dd1b3a9ac41b01fdff8922a68898cdc2f3597f8d19415bbd168f42f", "url": "https://news.google.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?oc=5", "external_url": "https://news.google.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?oc=5", "title": "EQS-News: Heidelberg Pharma berichtet \u00fcber das erste Halbjahr 2026 und positiven Gesch\u00e4ftsverlauf - boerse.de", "content_text": "EQS-News: Heidelberg Pharma berichtet \u00fcber das erste Halbjahr 2026 und positiven Gesch\u00e4ftsverlauf - boerse.de", "date_published": "2026-07-15T07:00:00+00:00", "authors": [{"name": "boerse.de"}], "tags": ["Market update", "HPHA"], "_sharemaestro": {"country": "Germany", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "HPHA", "name": "Heidelberg Pharma AG", "sentiment_url": "https://sharemaestro.com/sentiment/db29aa2b-d482-4579-a168-33a8e9531f1b/"}]}}, {"id": "source:cd44c871954c229fbf047baf998c53a6d52ade12885b8d9ecabd13351779cd3b", "url": "https://news.google.com/rss/articles/CBMidkFVX3lxTE5VTmlqMmdWc3ZuX1RYbDBNLWNHb3hTbnFRNks1VzVEalRKTURtLXpSdmNKWHpfUTJTdno1ZFZWR0dwU053MnQ2VUM4QW1sT082UGhtaFBSeXJHYXY1M1loT28wZ08yWGVfcnpxNURmWDE0ZGZTLVE?oc=5", "external_url": "https://news.google.com/rss/articles/CBMidkFVX3lxTE5VTmlqMmdWc3ZuX1RYbDBNLWNHb3hTbnFRNks1VzVEalRKTURtLXpSdmNKWHpfUTJTdno1ZFZWR0dwU053MnQ2VUM4QW1sT082UGhtaFBSeXJHYXY1M1loT28wZ08yWGVfcnpxNURmWDE0ZGZTLVE?oc=5", "title": "HPHA Prognose \u2014 Kursziel f\u00fcr 2027", "content_text": "HPHA Prognose \u2014 Kursziel f\u00fcr 2027", "date_published": "2026-06-27T05:30:12+00:00", "authors": [{"name": "TradingView"}], "tags": ["Market update", "HPHA"], "_sharemaestro": {"country": "Germany", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "HPHA", "name": "Heidelberg Pharma AG", "sentiment_url": "https://sharemaestro.com/sentiment/db29aa2b-d482-4579-a168-33a8e9531f1b/"}]}}, {"id": "source:b58ce1467adaaeff88b47b2e9707221b9892d813842ef1921b4451b63c77c9b7", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxNU2hQaEduVUZWc0o1N1hyZlpUYmEwQ2RORWNMNl9ab2JmWGhhVy1kbk1BTmlDMHkwZjk3QkJrUTFWNklESnoyR1BWUXhHM3RQSjBFeGl1clBlNlZXRTFfeTdkWlpJeW1pY0NRMjc3Z2cxaXllWG5kdHA1Y1lMc1lrU3hrMDVfRE11bFhiQkNjcGQ3c3RxZERSMHdiNC0yWllEdDRhRQ?oc=5", "external_url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxNU2hQaEduVUZWc0o1N1hyZlpUYmEwQ2RORWNMNl9ab2JmWGhhVy1kbk1BTmlDMHkwZjk3QkJrUTFWNklESnoyR1BWUXhHM3RQSjBFeGl1clBlNlZXRTFfeTdkWlpJeW1pY0NRMjc3Z2cxaXllWG5kdHA1Y1lMc1lrU3hrMDVfRE11bFhiQkNjcGQ3c3RxZERSMHdiNC0yWllEdDRhRQ?oc=5", "title": "Formycon Aktie: Umsatz verdreifacht, Ziel best\u00e4tigt", "content_text": "Formycon Aktie: Umsatz verdreifacht, Ziel best\u00e4tigt", "date_published": "2026-05-28T07:00:00+00:00", "authors": [{"name": "B\u00f6rse Express"}], "tags": ["Market update", "FYB"], "_sharemaestro": {"country": "Germany", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "FYB", "name": "Formycon AG", "sentiment_url": "https://sharemaestro.com/sentiment/ecf778e0-d8d5-4981-9874-3c9123d8ff80/"}]}}, {"id": "source:0356f0eba2689187c337ff3ff6434507a0a668fdd58c1b632a8642b3c92d0ea9", "url": "https://news.google.com/rss/articles/CBMifEFVX3lxTE9wWjJ6SERiVVZkUUx4MS1HWmdVZDQxV2VjWlZPS1pPM1o0cTdrNjBSeWFNVmFtOHlyU092NkhiNTJIWnhyU0RZbjFhVlVpby1JSEFKZVc2al8yWkg2MF9sRVBBeWtmZVlGT01oZEQ5djFnSVpSZmpZOGpCM2jSAYIBQVVfeXFMTm9IQWdySEdzbS02N2pveGdoZGtLMFh5TVlfNFNULUc2VHQyZzQwWkRYOVRwSk55UGtqdlJ4alowdFVNeWh1TWl2Uy1SMG5zeGlJUXhtSXR0U2oteV9wMERHV3BMdmlFeUxlajNBVUV2UHYzOUxPbFQxN3NveEVoQ25JQQ?oc=5", "external_url": "https://news.google.com/rss/articles/CBMifEFVX3lxTE9wWjJ6SERiVVZkUUx4MS1HWmdVZDQxV2VjWlZPS1pPM1o0cTdrNjBSeWFNVmFtOHlyU092NkhiNTJIWnhyU0RZbjFhVlVpby1JSEFKZVc2al8yWkg2MF9sRVBBeWtmZVlGT01oZEQ5djFnSVpSZmpZOGpCM2jSAYIBQVVfeXFMTm9IQWdySEdzbS02N2pveGdoZGtLMFh5TVlfNFNULUc2VHQyZzQwWkRYOVRwSk55UGtqdlJ4alowdFVNeWh1TWl2Uy1SMG5zeGlJUXhtSXR0U2oteV9wMERHV3BMdmlFeUxlajNBVUV2UHYzOUxPbFQxN3NveEVoQ25JQQ?oc=5", "title": "Formycon verdreifacht Umsatz \u2013 EBITDA-Verlust schrumpft deutlich", "content_text": "Formycon verdreifacht Umsatz \u2013 EBITDA-Verlust schrumpft deutlich", "date_published": "2026-05-28T07:00:00+00:00", "authors": [{"name": "4investors.de"}], "tags": ["Market update", "FYB"], "_sharemaestro": {"country": "Germany", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "FYB", "name": "Formycon AG", "sentiment_url": "https://sharemaestro.com/sentiment/ecf778e0-d8d5-4981-9874-3c9123d8ff80/"}]}}, {"id": "source:3f6703a077ddc61b93779647bd7fcd50d114b49e936281d81d7eaf548487b69a", "url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxONWx0eVVuV0dCTEdUZk91dWlmLWtSN1E0TFk2MDJFVDNxb2dGWnpWcU9JV0FFX2dISVhUdHBtaHNDbGN1NGhkbnVaV3RLOVZlYTBXMGFEcldtVFdjSWM5eHl4YkJ3dTdIdEpzSll3Xzd5bFpVQWt0ak9hWGVvTEd0a2x4b1pRRkFpa0x5REtZN2o1aHFtbVVpRk93eXdEREdUQk40UjZZU0lmak13TU0wM2pvSElYcEwyXzhXQV9JQ0RVQlBBNlE?oc=5", "external_url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxONWx0eVVuV0dCTEdUZk91dWlmLWtSN1E0TFk2MDJFVDNxb2dGWnpWcU9JV0FFX2dISVhUdHBtaHNDbGN1NGhkbnVaV3RLOVZlYTBXMGFEcldtVFdjSWM5eHl4YkJ3dTdIdEpzSll3Xzd5bFpVQWt0ak9hWGVvTEd0a2x4b1pRRkFpa0x5REtZN2o1aHFtbVVpRk93eXdEREdUQk40UjZZU0lmak13TU0wM2pvSElYcEwyXzhXQV9JQ0RVQlBBNlE?oc=5", "title": "Formycon meldet Q1 2026 mit Umsatzsprung und besserem EBITDA \u2013 Prognose f\u00fcr 2026 bleibt best\u00e4tigt", "content_text": "Formycon meldet Q1 2026 mit Umsatzsprung und besserem EBITDA \u2013 Prognose f\u00fcr 2026 bleibt best\u00e4tigt", "date_published": "2026-05-28T07:00:00+00:00", "authors": [{"name": "Goldesel.de"}], "tags": ["Market update", "FYB"], "_sharemaestro": {"country": "Germany", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "FYB", "name": "Formycon AG", "sentiment_url": "https://sharemaestro.com/sentiment/ecf778e0-d8d5-4981-9874-3c9123d8ff80/"}]}}, {"id": "source:abd0ee8dd3570b4aa606845024522e6fe2480ae0e81bf1ef26b44b866f3a00ba", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxPSkRrWV9jNTZZU3VvMkJfSkRPRFF1OWwxQXlVUjhlQk9hOUdwZ2tzR2RXcUlYSDZZZE1XaEZNaWoxVXRfd3J3UlM2U0d6ZU54eGRQeTRxRFhrcjBOWS1PbGl2dDdsUUJianR2bFBCRThsX0NIVDY4WGJDZWdmQmUyV1dYOUdzaGlmRVVFYTFqdl8wX1J2NVNjcTRtZy1fU3llS0hZSUduUUZVUFR6OGlmb1ZNczZOdw?oc=5", "external_url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxPSkRrWV9jNTZZU3VvMkJfSkRPRFF1OWwxQXlVUjhlQk9hOUdwZ2tzR2RXcUlYSDZZZE1XaEZNaWoxVXRfd3J3UlM2U0d6ZU54eGRQeTRxRFhrcjBOWS1PbGl2dDdsUUJianR2bFBCRThsX0NIVDY4WGJDZWdmQmUyV1dYOUdzaGlmRVVFYTFqdl8wX1J2NVNjcTRtZy1fU3llS0hZSUduUUZVUFR6OGlmb1ZNczZOdw?oc=5", "title": "Vertex Pharmaceuticals Stock: Q1 2026 Revenue Hits $2.99B With Full-Year Guidance Intact", "content_text": "Vertex Pharmaceuticals Stock: Q1 2026 Revenue Hits $2.99B With Full-Year Guidance Intact", "date_published": "2026-05-05T07:00:00+00:00", "authors": [{"name": "TIKR.com"}], "tags": ["Earnings", "VX1"], "_sharemaestro": {"country": "Germany", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "VX1", "name": "Vertex Pharmaceuticals Incorporated", "sentiment_url": "https://sharemaestro.com/sentiment/0a10da90-393d-44b4-8a20-d4e106ccaad9/"}]}}, {"id": "source:018911477a32bfa6cc403eb4fbfa0c22330952d5eb1700333303e100b9f959da", "url": "https://news.google.com/rss/articles/CBMikgFBVV95cUxNRWJZOHFTRmJ1UW9HWUdTMVRMVlJ5cy1xSlp0RVJMZnFaTFl3bmVoTl9sTXhCZzdWTkRzZFZYSTdXdUdxT1Y0YnBSaTJnY19vRm9jRlF5ZHNnT21pbFR1ekI4b0ExOTZ0VkFocEQzLUZtMTB4T2xMVjhwOW1PVDM1VFgydjFQS0FPdXY3Wi0zdWtGdw?oc=5", "external_url": "https://news.google.com/rss/articles/CBMikgFBVV95cUxNRWJZOHFTRmJ1UW9HWUdTMVRMVlJ5cy1xSlp0RVJMZnFaTFl3bmVoTl9sTXhCZzdWTkRzZFZYSTdXdUdxT1Y0YnBSaTJnY19vRm9jRlF5ZHNnT21pbFR1ekI4b0ExOTZ0VkFocEQzLUZtMTB4T2xMVjhwOW1PVDM1VFgydjFQS0FPdXY3Wi0zdWtGdw?oc=5", "title": "AtaiBeckley Inc.: Konsensus der Analysten und Kursziel | A41WEP | US04650F1012", "content_text": "AtaiBeckley Inc.: Konsensus der Analysten und Kursziel | A41WEP | US04650F1012", "date_published": "2026-01-04T13:13:31+00:00", "authors": [{"name": "MarketScreener Deutschland"}], "tags": ["Market update", "B72"], "_sharemaestro": {"country": "Germany", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "B72", "name": "AtaiBeckley Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/1fda33bb-846a-4e57-82ce-99a6d160480d/"}]}}, {"id": "source:c52dae569b59447e0e2a728e7965d25bb8e7d4f6d8649020873fd239c2519d43", "url": "https://news.google.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?oc=5", "external_url": "https://news.google.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?oc=5", "title": "Was Sie \u00fcber die Newron Pharmaceuticals S.p.A. (VTX:NWRN) Analyst Downgrade heute wissen m\u00fcssen", "content_text": "Was Sie \u00fcber die Newron Pharmaceuticals S.p.A. (VTX:NWRN) Analyst Downgrade heute wissen m\u00fcssen", "date_published": "2025-12-16T08:00:00+00:00", "authors": [{"name": "simplywall.st"}], "tags": ["Analyst action", "NP5"], "_sharemaestro": {"country": "Germany", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "NP5", "name": "Newron Pharmaceuticals S.p.A.", "sentiment_url": "https://sharemaestro.com/sentiment/95ec0423-02a6-4ee0-a560-c822ff1bf36c/"}]}}, {"id": "source:7ebde8bf5431bf2cd66f15abdc1d9d8c4fdfe8015d5fe653f5b101940294b059", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxQdGNWOC02TDE3cy1ITjBzcU1ybTYyNjhTNEhhYWtxZmp3WURkTjFSekwtdEVHbE9LSV9oRnhaV3Jha255eHMwMVFaWldMSkJOLV9XcF9id0NoajZoUEUtNmRrcGNXTWkxZERDNkZ6QzVieGxLRWs2cW9uNHRnQ2gxbk11bzBYLWIzNFVWVy1mcWpmV19pbXA4azV6MWhiY1BLOFFGdnJqWjAyWThEV1dVTm1LMHQteU56TjNZbmx6bFVVRFp5RExrbzlVWFFjOGs5TExRMHJsVnJUcjhscUNqUEh5b2ZWUQ?oc=5", "external_url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxQdGNWOC02TDE3cy1ITjBzcU1ybTYyNjhTNEhhYWtxZmp3WURkTjFSekwtdEVHbE9LSV9oRnhaV3Jha255eHMwMVFaWldMSkJOLV9XcF9id0NoajZoUEUtNmRrcGNXTWkxZERDNkZ6QzVieGxLRWs2cW9uNHRnQ2gxbk11bzBYLWIzNFVWVy1mcWpmV19pbXA4azV6MWhiY1BLOFFGdnJqWjAyWThEV1dVTm1LMHQteU56TjNZbmx6bFVVRFp5RExrbzlVWFFjOGs5TExRMHJsVnJUcjhscUNqUEh5b2ZWUQ?oc=5", "title": "Formycon-Aktie rot: Prognose best\u00e4tigt - Umsatzeinbruch und h\u00f6herer operativer Verlust", "content_text": "Formycon-Aktie rot: Prognose best\u00e4tigt - Umsatzeinbruch und h\u00f6herer operativer Verlust", "date_published": "2025-11-13T08:00:00+00:00", "authors": [{"name": "finanzen.net"}], "tags": ["Market update", "FYB"], "_sharemaestro": {"country": "Germany", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "FYB", "name": "Formycon AG", "sentiment_url": "https://sharemaestro.com/sentiment/ecf778e0-d8d5-4981-9874-3c9123d8ff80/"}]}}, {"id": "source:56dd853748e37df35ca3225b249c32a0fbf8a58b671304693ffb1466f8d07c8d", "url": "https://news.google.com/rss/articles/CBMifEFVX3lxTE5OWk5DcFZQUWFkY29fc3AyZ2V3Skc0ZzhHb2E4bjg0ZHlka2VUSUZQM2pleHhzdUVQOE5ZeUpUR2RSci1sckVuYXpUOUFEaXJaT0E1OUxKWDdXUWw1ZzRvSUFmMjdOQU11d2VaUkg5RWZNSDZ2WjdlNmx0c2_SAYIBQVVfeXFMT0lPWHIycXhFZXk3aDdicklTN0RaS3h4TDl6TGdkdnYwckJ5bm1nczBTS0tNRWRnWVZEYndqVHJxX0Y2NXNNMkh4dlRaVTNlTlNDQTRVQTlJa2tJaFh4V21UeVhuTE40cEQyWjg4d2RpM2szS1RvUU5JRG9pRW9KVHc1QQ?oc=5", "external_url": "https://news.google.com/rss/articles/CBMifEFVX3lxTE5OWk5DcFZQUWFkY29fc3AyZ2V3Skc0ZzhHb2E4bjg0ZHlka2VUSUZQM2pleHhzdUVQOE5ZeUpUR2RSci1sckVuYXpUOUFEaXJaT0E1OUxKWDdXUWw1ZzRvSUFmMjdOQU11d2VaUkg5RWZNSDZ2WjdlNmx0c2_SAYIBQVVfeXFMT0lPWHIycXhFZXk3aDdicklTN0RaS3h4TDl6TGdkdnYwckJ5bm1nczBTS0tNRWRnWVZEYndqVHJxX0Y2NXNNMkh4dlRaVTNlTlNDQTRVQTlJa2tJaFh4V21UeVhuTE40cEQyWjg4d2RpM2szS1RvUU5JRG9pRW9KVHc1QQ?oc=5", "title": "Heidelberg Pharma senkt Prognose und streicht 75 Prozent der Stellen", "content_text": "Heidelberg Pharma senkt Prognose und streicht 75 Prozent der Stellen", "date_published": "2025-10-09T07:00:00+00:00", "authors": [{"name": "4investors.de"}], "tags": ["Market update", "HPHA"], "_sharemaestro": {"country": "Germany", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "HPHA", "name": "Heidelberg Pharma AG", "sentiment_url": "https://sharemaestro.com/sentiment/db29aa2b-d482-4579-a168-33a8e9531f1b/"}]}}, {"id": "source:8488615ce367cc46e7445cf97dfadfb6d7c4d30c615ef9e64b35fabbb218efac", "url": "https://news.google.com/rss/articles/CBMifEFVX3lxTFBaQTAxbDlnUFBkSHVkVERSVHpHMkZHNTZleFBPLTl4bnZ1czFCQW1hMVZ0Rnd5RjZiYTFWQnRYdGt5emdRVW5MQUhRQ2N1Y196eDZMaFdWYmRpY2d1b0hLd3BMWldFcm55eXpfVVNFOW9aQllpNnVRNHE5RDHSAYIBQVVfeXFMUFlrNERKNzZLdGM2SlJFREwweDVad0VOUFVPS0htU2M4T0lfam93Q2dvZlhJdWJRcTlzUmVJN29nS0dYRjZNRE5WWU5vc25EbXpNOVQ2ckZsYWttSXRweWhWc3owbzU1R1dISXJjekVpN25UbE5PdkFERU1DSFV2bXNxdw?oc=5", "external_url": "https://news.google.com/rss/articles/CBMifEFVX3lxTFBaQTAxbDlnUFBkSHVkVERSVHpHMkZHNTZleFBPLTl4bnZ1czFCQW1hMVZ0Rnd5RjZiYTFWQnRYdGt5emdRVW5MQUhRQ2N1Y196eDZMaFdWYmRpY2d1b0hLd3BMWldFcm55eXpfVVNFOW9aQllpNnVRNHE5RDHSAYIBQVVfeXFMUFlrNERKNzZLdGM2SlJFREwweDVad0VOUFVPS0htU2M4T0lfam93Q2dvZlhJdWJRcTlzUmVJN29nS0dYRjZNRE5WWU5vc25EbXpNOVQ2ckZsYWttSXRweWhWc3owbzU1R1dISXJjekVpN25UbE5PdkFERU1DSFV2bXNxdw?oc=5", "title": "Heidelberg Pharma: Neue Prognose f\u00fcr 2025", "content_text": "Heidelberg Pharma: Neue Prognose f\u00fcr 2025", "date_published": "2025-10-06T07:00:00+00:00", "authors": [{"name": "4investors.de"}], "tags": ["Market update", "HPHA"], "_sharemaestro": {"country": "Germany", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "HPHA", "name": "Heidelberg Pharma AG", "sentiment_url": "https://sharemaestro.com/sentiment/db29aa2b-d482-4579-a168-33a8e9531f1b/"}]}}, {"id": "source:b4ffb0aef25e6856fb72059f7067c8e7aa583bd705acb6227d3cb51b5512f62d", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxPQjBoT0w4cmtCbl81ODlibW5UbUE2NzhweUdQRVBzLWNkSmxqUkNZejdCZzBINm5VNFd3bkVZbWdTQlMwbTV5em1yd240MnhaU01jNXJsV0Y1dG96LVB3cVY3T3ozbUdMRTlOejBsNkJoMFlFX21INDZOZ09CbGd2Wkc1VXNRb1M5MU1rMnZwaG1UVTU2MVZSZnpWRkF3cXF2UFB2UGhtTkNydllX?oc=5", "external_url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxPQjBoT0w4cmtCbl81ODlibW5UbUE2NzhweUdQRVBzLWNkSmxqUkNZejdCZzBINm5VNFd3bkVZbWdTQlMwbTV5em1yd240MnhaU01jNXJsV0Y1dG96LVB3cVY3T3ozbUdMRTlOejBsNkJoMFlFX21INDZOZ09CbGd2Wkc1VXNRb1M5MU1rMnZwaG1UVTU2MVZSZnpWRkF3cXF2UFB2UGhtTkNydllX?oc=5", "title": "Sernova Biotherapeutics: Kooperation befl\u00fcgelt die Aktie", "content_text": "Sernova Biotherapeutics: Kooperation befl\u00fcgelt die Aktie", "date_published": "2025-07-09T07:00:00+00:00", "authors": [{"name": "B\u00f6rse Express"}], "tags": ["Market update", "PSH0"], "_sharemaestro": {"country": "Germany", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "PSH0", "name": "Sernova Biotherapeutics Inc", "sentiment_url": "https://sharemaestro.com/sentiment/3c4f1fa3-2ed6-4c60-a267-7c615bdc2728/"}]}}, {"id": "source:0f44bc3316cd469a5ce5a0164f22ab030d238034f88a32d1569aba7a2366f8ed", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxQZnJvZ29Va1pyUURyV1ZoQVFSdUJmR0ZHcEpyelgxVjJrSjVOWlJlcDVoOTJQM1R0TFJmaXNHVXhQVlR5TGU0ZUFvQ1U0UUwtTnJYMGVVOERHVXV4bWZqZTJzSmR2M1ZrVjRzRXNRUDNKeER5QjZRakE2OEk0SHJUMUNZWTUtX256WF9OVzRtVGlLVDlYUngyQlN6OGM4Zw?oc=5", "external_url": "https://news.google.com/rss/articles/CBMingFBVV95cUxQZnJvZ29Va1pyUURyV1ZoQVFSdUJmR0ZHcEpyelgxVjJrSjVOWlJlcDVoOTJQM1R0TFJmaXNHVXhQVlR5TGU0ZUFvQ1U0UUwtTnJYMGVVOERHVXV4bWZqZTJzSmR2M1ZrVjRzRXNRUDNKeER5QjZRakE2OEk0SHJUMUNZWTUtX256WF9OVzRtVGlLVDlYUngyQlN6OGM4Zw?oc=5", "title": "Sernova Biotherapeutics Inc: Konsensus der Analysten und Kursziel | A411DW | CA81752F1062", "content_text": "Sernova Biotherapeutics Inc: Konsensus der Analysten und Kursziel | A411DW | CA81752F1062", "date_published": "2025-02-11T18:03:31+00:00", "authors": [{"name": "MarketScreener Deutschland"}], "tags": ["Market update", "PSH0"], "_sharemaestro": {"country": "Germany", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "PSH0", "name": "Sernova Biotherapeutics Inc", "sentiment_url": "https://sharemaestro.com/sentiment/3c4f1fa3-2ed6-4c60-a267-7c615bdc2728/"}]}}, {"id": "source:2e1a384db72121b532581a5c7d7c3258b763fa9cc1036e67d1984c4b8033b263", "url": "https://news.google.com/rss/articles/CBMifEFVX3lxTE0wamRuX25ya2c4RzdFM3R1Rnk1OWtGQXhhVk0zdlhGcnNlWUZyM1BndThXSzRBNHZrYVNNSHhpQ1g0ZHFfNjIxVkNqNFJqdDYzYlk1ZkxGZVpZVmhjLW53S1NJdUlqM1BERmdzRXJtN2wwa0VqeVpDeDlmMXPSAYIBQVVfeXFMTWFLRVZzVDQxekpjMmJndUk4a2pYb3dtekZ6OVFvaDd2aFZLQlViWi1oOE5wREJHbl85eHZWN0JUS2kyOVR1eHVEQmtQcjJ6Rk16TjgwS3hZT1ZsdkFTU0V1V296Vk9ieG1TeWt3eVZ5MThQM2VsVnZZbVJxUjk3SFdYdw?oc=5", "external_url": "https://news.google.com/rss/articles/CBMifEFVX3lxTE0wamRuX25ya2c4RzdFM3R1Rnk1OWtGQXhhVk0zdlhGcnNlWUZyM1BndThXSzRBNHZrYVNNSHhpQ1g0ZHFfNjIxVkNqNFJqdDYzYlk1ZkxGZVpZVmhjLW53S1NJdUlqM1BERmdzRXJtN2wwa0VqeVpDeDlmMXPSAYIBQVVfeXFMTWFLRVZzVDQxekpjMmJndUk4a2pYb3dtekZ6OVFvaDd2aFZLQlViWi1oOE5wREJHbl85eHZWN0JUS2kyOVR1eHVEQmtQcjJ6Rk16TjgwS3hZT1ZsdkFTU0V1V296Vk9ieG1TeWt3eVZ5MThQM2VsVnZZbVJxUjk3SFdYdw?oc=5", "title": "Heidelberg Pharma: Kosten fallen 2024 geringer als erwartet aus", "content_text": "Heidelberg Pharma: Kosten fallen 2024 geringer als erwartet aus", "date_published": "2024-10-01T07:00:00+00:00", "authors": [{"name": "4investors.de"}], "tags": ["Market update", "HPHA"], "_sharemaestro": {"country": "Germany", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "HPHA", "name": "Heidelberg Pharma AG", "sentiment_url": "https://sharemaestro.com/sentiment/db29aa2b-d482-4579-a168-33a8e9531f1b/"}]}}, {"id": "source:25f51c70bd58e494fa278084f9d27d2325307b26901b34c4b75d2b7700df5348", "url": "https://news.google.com/rss/articles/CBMiekFVX3lxTE82d2F3RFUzdG9BWC1VQmN0WWE5U1BCaURURk5pNGpTOUtfeE1mQlhpWWRjS1h4Um5MTGdqYlNvdGNIOS13Wjl2OE10MWVENGo0dEhfb2FFaldid1ZqUWxZRDh5Sm9DT0hPSjIwcElqS0xhTE96eXE1VFJn?oc=5", "external_url": "https://news.google.com/rss/articles/CBMiekFVX3lxTE82d2F3RFUzdG9BWC1VQmN0WWE5U1BCaURURk5pNGpTOUtfeE1mQlhpWWRjS1h4Um5MTGdqYlNvdGNIOS13Wjl2OE10MWVENGo0dEhfb2FFaldid1ZqUWxZRDh5Sm9DT0hPSjIwcElqS0xhTE96eXE1VFJn?oc=5", "title": "Formycon AG: Finanzdaten Prognosen Sch\u00e4tzungen und Erwartungen | A1EWVY | DE000A1EWVY8", "content_text": "Formycon AG: Finanzdaten Prognosen Sch\u00e4tzungen und Erwartungen | A1EWVY | DE000A1EWVY8", "date_published": "2024-07-23T09:57:52+00:00", "authors": [{"name": "MarketScreener Deutschland"}], "tags": ["Market update", "FYB"], "_sharemaestro": {"country": "Germany", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "FYB", "name": "Formycon AG", "sentiment_url": "https://sharemaestro.com/sentiment/ecf778e0-d8d5-4981-9874-3c9123d8ff80/"}]}}, {"id": "source:cfb082a2db7d584b43cfc38854bf30825c67f1d461c0d80835958e550b04b25e", "url": "https://news.google.com/rss/articles/CBMifEFVX3lxTE1QSEZhYk0teWhJZzUybTJHdHRVNnQtQVFyeUNDSnl0WjQ0cUJqZ25kd2sxMnhaZnhmdkllMUJGQ0pxM0g5Y1hYSWNXTkdLUE5aajdFd1oxNzYtVEdfdERLQnE2LWdJMW85TkZYSnMyRTBfUFJFZ28xbUJRSW7SAYIBQVVfeXFMTUhINjM3dzA5U0g3VVhxbGVsbE40R1NNRlg2OVQyNlo0R0o3ckdReExrMV9sUFltNFh6c0ZuYjRQZDRWd0RkbkJmTW8ta3gxS3dWc2w1MGtNTlNTdTVJMndTZENxMFdjYnVVY2FlN1lvb3NJUmpvY2JaRFpfR19NMjhjUQ?oc=5", "external_url": "https://news.google.com/rss/articles/CBMifEFVX3lxTE1QSEZhYk0teWhJZzUybTJHdHRVNnQtQVFyeUNDSnl0WjQ0cUJqZ25kd2sxMnhaZnhmdkllMUJGQ0pxM0g5Y1hYSWNXTkdLUE5aajdFd1oxNzYtVEdfdERLQnE2LWdJMW85TkZYSnMyRTBfUFJFZ28xbUJRSW7SAYIBQVVfeXFMTUhINjM3dzA5U0g3VVhxbGVsbE40R1NNRlg2OVQyNlo0R0o3ckdReExrMV9sUFltNFh6c0ZuYjRQZDRWd0RkbkJmTW8ta3gxS3dWc2w1MGtNTlNTdTVJMndTZENxMFdjYnVVY2FlN1lvb3NJUmpvY2JaRFpfR19NMjhjUQ?oc=5", "title": "Formycon best\u00e4tigt Prognose f\u00fcr 2024 - \u00dcbernahme \u201eunwahrscheinlich\u201d", "content_text": "Formycon best\u00e4tigt Prognose f\u00fcr 2024 - \u00dcbernahme \u201eunwahrscheinlich\u201d", "date_published": "2024-06-03T07:00:00+00:00", "authors": [{"name": "4investors.de"}], "tags": ["Market update", "FYB"], "_sharemaestro": {"country": "Germany", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "FYB", "name": "Formycon AG", "sentiment_url": "https://sharemaestro.com/sentiment/ecf778e0-d8d5-4981-9874-3c9123d8ff80/"}]}}]}